tetano
Editor, Senior Moderator
Immunol
. 2020 Oct 30;ji2000767.
doi: 10.4049/jimmunol.2000767. Online ahead of print.
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19
Erik H Vogelzang[SUP] 1 2 [/SUP], Floris C Loeff[SUP] 3 4 [/SUP], Ninotska I L Derksen[SUP] 3 [/SUP], Simone Kruithof[SUP] 3 [/SUP], Pleuni Ooijevaar-de Heer[SUP] 3 [/SUP], Gerard van Mierlo[SUP] 3 [/SUP], Federica Linty[SUP] 5 [/SUP], Juk Yee Mok[SUP] 6 [/SUP], Wim van Esch[SUP] 6 [/SUP], Sanne de Bruin[SUP] 7 [/SUP], Alexander P J Vlaar[SUP] 7 [/SUP], Amsterdam University Medical Center COVID-19 Biobank Study Group,; Bart Seppen[SUP] 1 [/SUP], Maureen Leeuw[SUP] 1 [/SUP], Anne J G van Oudheusden[SUP] 8 [/SUP], Anton G M Buiting[SUP] 8 [/SUP], Kin Ki Jim[SUP] 2 9 [/SUP], Hans Vrielink[SUP] 10 [/SUP], Francis Swaneveld[SUP] 10 [/SUP], Gestur Vidarsson[SUP] 5 [/SUP], C Ellen van der Schoot[SUP] 5 [/SUP], Peter C Wever[SUP] 9 [/SUP], Wentao Li[SUP] 11 [/SUP], Frank van Kuppeveld[SUP] 11 [/SUP], Jean-Luc Murk[SUP] 8 [/SUP], Berend Jan Bosch[SUP] 11 [/SUP], Gerrit-Jan Wolbink[SUP] 1 3 12 [/SUP], Theo Rispens[SUP] 13 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only mild disease that may evoke relatively low Ab titers compared with patients admitted to hospitals. Generally, total Ab bridging assays combine good sensitivity with high specificity. Therefore, we developed sensitive total Ab bridging assays for detection of SARS-CoV-2 Abs to the receptor-binding domain (RBD) and nucleocapsid protein in addition to conventional isotype-specific assays. Ab kinetics was assessed in PCR-confirmed, hospitalized coronavirus disease 2019 (COVID-19) patients (n = 41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confirmed hospital care workers (n = 47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n = 14). In nonhospitalized patients, the Ab response to RBD is weaker but follows similar kinetics, as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; nucleocapsid protein Abs emerged less consistently. Furthermore, we demonstrated the feasibility of finger-prick sampling for Ab detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 Abs in hospitalized and nonhospitalized patients and are therefore well suited to conduct seroprevalence studies.
. 2020 Oct 30;ji2000767.
doi: 10.4049/jimmunol.2000767. Online ahead of print.
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19
Erik H Vogelzang[SUP] 1 2 [/SUP], Floris C Loeff[SUP] 3 4 [/SUP], Ninotska I L Derksen[SUP] 3 [/SUP], Simone Kruithof[SUP] 3 [/SUP], Pleuni Ooijevaar-de Heer[SUP] 3 [/SUP], Gerard van Mierlo[SUP] 3 [/SUP], Federica Linty[SUP] 5 [/SUP], Juk Yee Mok[SUP] 6 [/SUP], Wim van Esch[SUP] 6 [/SUP], Sanne de Bruin[SUP] 7 [/SUP], Alexander P J Vlaar[SUP] 7 [/SUP], Amsterdam University Medical Center COVID-19 Biobank Study Group,; Bart Seppen[SUP] 1 [/SUP], Maureen Leeuw[SUP] 1 [/SUP], Anne J G van Oudheusden[SUP] 8 [/SUP], Anton G M Buiting[SUP] 8 [/SUP], Kin Ki Jim[SUP] 2 9 [/SUP], Hans Vrielink[SUP] 10 [/SUP], Francis Swaneveld[SUP] 10 [/SUP], Gestur Vidarsson[SUP] 5 [/SUP], C Ellen van der Schoot[SUP] 5 [/SUP], Peter C Wever[SUP] 9 [/SUP], Wentao Li[SUP] 11 [/SUP], Frank van Kuppeveld[SUP] 11 [/SUP], Jean-Luc Murk[SUP] 8 [/SUP], Berend Jan Bosch[SUP] 11 [/SUP], Gerrit-Jan Wolbink[SUP] 1 3 12 [/SUP], Theo Rispens[SUP] 13 [/SUP]
Affiliations
- PMID: 33127820
- DOI: 10.4049/jimmunol.2000767
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only mild disease that may evoke relatively low Ab titers compared with patients admitted to hospitals. Generally, total Ab bridging assays combine good sensitivity with high specificity. Therefore, we developed sensitive total Ab bridging assays for detection of SARS-CoV-2 Abs to the receptor-binding domain (RBD) and nucleocapsid protein in addition to conventional isotype-specific assays. Ab kinetics was assessed in PCR-confirmed, hospitalized coronavirus disease 2019 (COVID-19) patients (n = 41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confirmed hospital care workers (n = 47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n = 14). In nonhospitalized patients, the Ab response to RBD is weaker but follows similar kinetics, as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; nucleocapsid protein Abs emerged less consistently. Furthermore, we demonstrated the feasibility of finger-prick sampling for Ab detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 Abs in hospitalized and nonhospitalized patients and are therefore well suited to conduct seroprevalence studies.